Compare Southwest Airlines Co (LUV) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Southwest Airlines Co vs Travere Therapeutics Inc. Common Stock — how do they compare? Southwest Airlines Co trades at $39.51 (market cap $19.89B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Southwest Airlines Co is far larger — about 4.1× Travere Therapeutics Inc. Common Stock's market cap, and Southwest Airlines Co pays a 1.77% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Southwest Airlines Co for 66 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| LUV | TVTX | |
|---|---|---|
Market Cap | $19.89B | $4.88B |
Volume | 3,985,163 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $54.80 | $67.52 |
52-Week Low | $29.67 | $26.79 |
Typical Hold Time | 66 Days | 0 Days |
Enterprise Value | $22.98B | $5.01B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Southwest Airlines (LUV) trades at $40.65, down 0.27% on the day, with technical indicators showing a bearish trend while fundamentals reveal a mixed picture. The company reported revenue growth to $28.06 billion in 2025 but saw net income margin compression to 1.57%. Recent earnings show volatility with a significant Q2 2026 beat but a Q1 2026 miss. Analyst sentiment is divided with 42% buy ratings and a $49.61 consensus price target representing 22% upside potential.
LUV presents a value opportunity with attractive valuation metrics (P/S 0.71, EV/EBITDA 8.28) and ongoing commercial transformation driving revenue growth. However, investors face risks from fuel cost volatility, competitive pressures, and inconsistent earnings performance. The stock's current technical weakness near support levels may offer entry points for long-term investors betting on the company's premium service initiatives and projected 2026 margin improvement to 2.78%.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
